SynthesisFrontiers in pharmacology2026

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a systematic review and meta-analysis.

Meng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.